Ipilimumab and Nivolumab With CRT May Be a Bladder-Sparing Treatment in MIBC - Oncology Nurse Advisor The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.

Combined neoadjuvant treatment with ipilimumab and nivolumab followed by CRT shows promise as a bladder-sparing treatment for muscle-invasive #bladdercancer. From @natmed.nature.com and @renalurologynews.bsky.social.

Read more: ➡️ https://bit.ly/3MZPjiH

#MIBC #blcsm #UroOnc

🧬 Missed our webinar on microRNA studies in testicular germ cell tumours?

📺 Watch now: youtu.be/ezg8w7SkOw8

📰 Subscribe: tinyurl.com/ERNeUROGENne...

#EUfunded #EU4Health #RareDisease #ERNs #UroOnc #EUCancerPlan #EUCancerMission #UroSoMe
@ec.europa.eu @jardinjointaction.bsky.social

🧬 Discover how microRNAs can improve diagnosis & monitoring of testicular cancer!

📅 Wed 4 Feb @ 18:00 CET

🎙 João Lobo shares translational research & clinical insights

🔗 Register: events.zoom.us/ev/ArCdYFymJ...

#EUfunded #UroOnc #RareDisease #ERNs @ec.europa.eu @jardinjointaction.bsky.social

🎥 Watch our webinar on Adrenal Cancer and Malignant Cysts with Hans Langenhuijsen & Nikola Knežević

📺 youtu.be/NK8dsUHF_dU

📰 tinyurl.com/ERNeUROGENne...

#EUfunded #EU4Health #RareDisease #ERNs #UroOnc #EUCancerPlan #EUCancerMission #UroSoMe @ec.europa.eu @jardinjointaction.bsky.social

🧬 Discover how microRNAs can improve diagnosis & monitoring of testicular cancer!

📅 Wed 4 Feb @ 18:00 CET

🎙 João Lobo shares translational research & clinical insights

🔗 Register: events.zoom.us/ev/ArCdYFymJ...

#EUfunded #UroOnc #RareDisease #ERNs @ec.europa.eu @jardinjointaction.bsky.social

🧬 Discover how microRNAs can improve diagnosis & monitoring of testicular cancer!

📅 Wed 4 Feb @ 18:00 CET

🎙 João Lobo shares translational research & clinical insights

🔗 Register: events.zoom.us/ev/ArCdYFymJ...

#EUfunded #UroOnc #RareDisease #ERNs @ec.europa.eu @jardinjointaction.bsky.social

🚨 Join @erneurogen.bsky.social for an expert-led webinar on Adrenal Cancer & Malignant Cysts

📅 Tonight @ 18:00 CET
🎙️ Hans Langenhuijsen & Nikola Knežević
🎓 EACCME accredited (live attendees)

🔗 events.zoom.us/ev/AuzZaVXQf...

#EUfunded #UroOnc #ERNs #RareDisease @jardinjointaction.bsky.social

🧠 Join @erneurogen.bsky.social for an expert-led webinar on Adrenal Cancer & Malignant Cysts

📅 Wed 28 Jan @ 18:00 CET
🎙️ Hans Langenhuijsen & Nikola Knežević
🎓 EACCME accredited (live attendees)

🔗 events.zoom.us/ev/AuzZaVXQf...

#EUfunded #UroOnc #ERNs #RareDisease @jardinjointaction.bsky.social

🧠 Join @erneurogen.bsky.social for an expert-led webinar on Adrenal Cancer & Malignant Cysts

📅 Wed 28 Jan @ 18:00 CET
🎙️ Hans Langenhuijsen & Nikola Knežević
🎓 EACCME accredited (live attendees)

🔗 events.zoom.us/ev/AuzZaVXQf...

#EUfunded #UroOnc #ERNs #RareDisease @jardinjointaction.bsky.social

Why it matters for #bladdercancer care: better risk-adapted bladder-sparing strategies, smarter use of biomarkers in decision-making, and trials built around what matters most to patients & survivors. #uroonc #MIBC

EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

EMBARK: final OS results of enzalutamide in hrBCR prostate cancer - VJOncology Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses final overall survival results from the Phase III...

Neal Shore, MD, FACS shares final OS data from EMBARK in high-risk BCR prostate cancer.

💊 Enzalutamide + leuprolide ↓ risk of death vs leuprolide alone
📈 Improved progression & skeletal outcomes
✅ Confirms enzalutamide-based therapy as SoC
🎥 buff.ly/LBEmrOa

#ProstateCancer #ESMO25 #UroOnc #UroSoMe

ESMO 2025: Novel Combinations Are Changing Standards of Care in Bladder Cancer ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Phase 3 data from multiple studies presented at #ESMO25 demonstrated that novel staging approaches along with new therapy combinations, such as EV plus pembrolizumab and disitamab vedotin plus toripalimab improved SO in patients with #bladdercancer.

https://bit.ly/4qMWKsC

#blcsm #UroOnc

FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...

Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25

COSMIC-313: transcriptomic predictors of metastatic sites in RCC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...

Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25

🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT

🎥 Watch: buff.ly/dIMvnoC

@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe

Uromigos on X: "The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G" / X The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. David Aggen discusses : Variant Histology Bladder Cancer. https://t.co/h3DFbgnz3G

🎶 Wondering how to tackle variant histologies in bladder cancer?

🎧 Watch here ⬇️

x.com/uromigos/sta...

@Uromigos @Dr_Aggen @BladderCancerUS
#BladderCancer #UroOnc #GUonc #PathTwitter

PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC - VJOncology Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which...

At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC:

💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS
📈 OS trend & manageable safety
✅ No major QoL impact

🎥 Watch: buff.ly/vSBfVPS

@myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM

CheckMate 274: 5-year results of adjuvant nivolumab in MIUC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year...

At #ESMO25, Clara Steiner, MD, presents 5-year results of CheckMate 274 in MIUC

💊 Adjuvant nivolumab vs placebo after surgery
📈 Sustained DFS, OS & disease-specific survival benefit
🧫 ctDNA-positive pts saw enhanced benefit
✅ No new safety concerns

🎥 Watch: buff.ly/ou4EvLv

#UroOnc #UroSoMe #Blcsm

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

At #ESMO25, Emmanuel Seront discusses the RENALUT trial of ¹⁷⁷Lu-PSMA-617 in metastatic ccRCC

💥 PSMA-targeted radioligand therapy after TKI + ICI progression
🎯 Evaluating response, PFS, OS, & safety
🧠 Imaging-guided treatment w/ added cycles for responders

🎥 buff.ly/sswLUyk

#kcms #UroOnc #UroSoME

RAISN: indocyanine green-guided lymph node dissection in testicular cancer - VJOncology Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...

⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:

🎥 buff.ly/kF09jHH

#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm

🚨 TONIGHT! Join us for a cutting-edge webinar on Stage II Testicular Germ Cell Tumours

👨‍⚕️Dr Arnout Alberts shares the latest in personalised, multidisciplinary care
📅 Wed 1 Oct @ 17:00 CEST
🎓 EACCME-accredited
🔗 bit.ly/eUROGEN01Oct25

#EUfunded #EU4Health #RareDisease #ERNs #UroOnc #UroSoMe

Join us for a cutting-edge webinar on Stage II Testicular Germ Cell Tumours 💥

👨‍⚕️Dr Arnout Alberts shares the latest in personalised, multidisciplinary care
📅 Wed 1 Oct @ 17:00 CEST
🎓 EACCME-accredited
🔗 bit.ly/eUROGEN01Oct25

#EUfunded #EU4Health #HealthUnion #RareDisease #ERNs #UroOnc #UroSoMe

Updates in the PROBASE study of risk adapted screening for prostate cancer - VJOncology Peter Albers, German Cancer Research Center (DKFZ), Heidelberg & Heinrich-Heine-University, Düsseldorf, Germany, comments on the PROBASE trial of risk adapted...

🎥 Peter Albers, MD, comments on PROBASE: men with negative biopsy unlikely to develop prostate cancer within 5 yrs. Doubling PSA values key to refining high-risk group & avoiding overdiagnosis.

➡️ buff.ly/4gKsdFN

#EAU25 #UroOnc #UroSoMe #PCSM #CTSM #TrialUpdate

Join us for a cutting-edge webinar on Stage II Testicular Germ Cell Tumours 💥

👨‍⚕️Dr Arnout Alberts shares the latest in personalised, multidisciplinary care
📅 Wed 1 Oct @ 17:00 CEST
🎓 EACCME-accredited
🔗 bit.ly/eUROGEN01Oct25

#EUfunded #EU4Health #HealthUnion #RareDisease #ERNs #UroOnc #UroSoMe

It’s #UrologyWeek! 🚻 Cancer patients face higher infection risks during treatment & recovery. Preventing & managing UTIs is critical to outcomes. 🔬

🔗 eurogen-ern.eu/urology-week...

#EUfunded #EU4Health #UroOnc #EUCancerPlan #EUCancerMission #RareDisease #ERNs

PSMA PET predictors of response to 225Ac-J591 in mCRPC - VJOncology Valentina Marulanda Corzo, MD, Weill Cornell Medicine, New York, NY, discusses findings from early-phase trials (NCT03276572, NCT04506567, NCT04886986, NCT04946370) assessing...

🎥 Valentina Marulanda Corzo, MD, discusses findings from early-phase trials assessing baseline and follow-up PSMA PET parameters in patients with mCRPC treated with 225Ac-J591:

➡️ buff.ly/777PV9f ⬅️

@ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UrsoSoMe #TrialUpdate #CTSM

Prognostic impact of PSA thresholds in mHSPC after ADT-ARPI - VJOncology Michael Ong, MD, BSc, FRCPC, The Ottawa Hospital Cancer Centre, Ottawa, Canada, comments on a real-world analysis from the IRONMAN...

🎥Michael Ong, MD, BSc, FRCPC, highlights the prognostic role of PSA in PC: levels >0.2 may signal worse outcomes, but treatment decisions shouldn’t be based on PSA alone. More research needed, especially for low-PSA patients

buff.ly/zZSr2sp

@ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UroSoMe

CONTACT-03: subgroup analysis of 2L cabozantinib ± atezolizumab in aRCC - VJOncology Cristina Suárez, MD, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain, discusses a subgroup analysis from the CONTACT-03 study (NCT04338269)...

🎥 Cristina Suárez (@vhio.bsky.social) discusses CONTACT-03 subgroup analysis on cabozantinib ± atezolizumab in advanced #RCC post-immunotherapy at #ASCO25. Key insights for treatment sequencing strategies.

🔗 buff.ly/uix2tBW

@ascocancer.bsky.social #KidneyCancer #RCC #GUsm #UroOnc #UroSoMe

Sexuality, intimacy & rare cancers. In this powerful @uroweb.org UROwebinar, ERN eUROGEN ePAG reps Rob Cornes & John Osborne share lived experiences after surgery.
🎥 Watch: www.youtube.com/watch?v=BayC...

#EUfunded #EU4Health #UroSoMe #UroOnc #EUCancerPlan #EUCancerMission #PenileCancer

Top 5 urologic oncology headlines you missed in July 2025 Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Check out our latest monthly recap, where we highlight notable advancements in urologic oncology from July 2025. #UroOnc

Sign up to view! www.urologytimes.com/view/top-5-u...